cmAngio® vs ZEUS System
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if you are looking to leverage existing mammography screenings to gain additional insights into a woman's cardiovascular health. This tool is ideal for identifying Breast Arterial Calcifications (BAC) as a potential early indicator of cardiovascular risk, without requiring any additional patient procedures or radiation exposure. It allows for a proactive, non-invasive assessment of cardiac risk during routine breast imaging.
View cmAngio® →Choose ZEUS System if…
Choose the ZEUS System if you need long-term, continuous cardiac monitoring to detect and characterize intermittent arrhythmias, such as Atrial Fibrillation. This AI-powered wearable solution is best suited for patients experiencing symptoms suggestive of an arrhythmia or those at risk who require extended ECG data analysis beyond a standard in-office exam. It provides comprehensive data for both symptomatic and asymptomatic cardiac events over several days.
View ZEUS System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | ZEUS System |
|---|---|---|
| Pricing | Paid, out-of-pocket | Not disclosed |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based (AWS EC2 platform), no on-premise hardware. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS SystemTool B (ZEUS System) offers a comprehensive web portal and mobile application (ZioSuite) for managing the entire cardiac monitoring workflow, from patient enrollment to report review, which streamlines clinical processes. Its wearable biosensors are designed for simplicity to improve patient compliance. While Tool A (cmAngiou00ae) emphasizes quick installation and DICOM compatibility for radiology workflows, Tool B's end-to-end management and patient-centric design provide a broader scope of usability.
Clinical Value
ZEUS SystemBoth tools are FDA-cleared and address significant clinical needs. Tool B (ZEUS System) provides robust, continuous, and clinically superior monitoring for critical cardiac arrhythmias like Atrial Fibrillation, with extensive clinical evidence demonstrating high sensitivity and specificity and a 99% physician agreement rate on reports. Tool A (cmAngiou00ae) offers a novel application of existing mammogram data for cardiovascular risk assessment, but Tool B's direct impact on the diagnosis and management of life-threatening cardiac conditions gives it a slight edge in immediate clinical impact.
Pricing & Value
TieNeither tool provides transparent public pricing information in the structured facts or through web searches. While Tool A (cmAngiou00ae) mentions potential 'no-cost implementation and service' offers, these are not guaranteed or universally available. Without concrete pricing details for either product, it is impossible to conduct a meaningful comparison of their respective value propositions.
Enterprise Readiness
ZEUS SystemBoth tools are FDA-cleared, HIPAA-compliant, and cloud-based, indicating strong foundational enterprise readiness. However, Tool B (ZEUS System) explicitly states it has a Business Associate Agreement (BAA) in place and offers HL7-based EHR integration, which are critical for seamless enterprise deployment and data exchange. Tool A (cmAngiou00ae) requires contacting the vendor for BAA details, presenting a minor hurdle for immediate transparency for enterprise clients.
Innovation
cmAngio®Tool A (cmAngiou00ae) demonstrates higher innovation by repurposing existing mammography data to detect Breast Arterial Calcifications (BAC) for cardiovascular risk assessment, transforming a routine breast cancer screening into a 'two-for-one' exam without additional radiation. This represents a novel application of AI to leverage incidental findings for broader preventative health. While Tool B (ZEUS System) refines and optimizes an existing diagnostic pathway with advanced AI and wearables, Tool A's approach is more fundamentally innovative in its use case.
Support & Docs
ZEUS SystemTool B (ZEUS System) provides readily accessible 'Instructions for Use' and 'Clinical Reference Manuals' online, along with dedicated patient support and customer care contact information. While Tool A (cmAngiou00ae) has general contact and support links on its website, Tool B's documentation appears more comprehensive and easily discoverable, indicating better support resources for users and patients.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | ZEUS System |
|---|---|---|
| Name | cmAngiou00ae | ZEUS System |
| Company | CureMetrix | iRhythm Technologies |
| Primary Function | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation. |
| Key Data Input | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | ECG data from wearable biosensors |
| Target Condition(s) Detected | Breast Arterial Calcifications (BAC) | Arrhythmias (e.g., Atrial Fibrillation) |
| Specialties Supported | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Family Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and ZEUS System.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or ZEUS System
Backers
Who funded each tool's parent company.